Introduction
Nitric oxide (NO) is a well-studied molecule that has been the source of much debate since its use as a mediator of vascular tone was first discovered in 1987; indeed, NO was named the 'molecule of the year' by the journal Science in 1992. 1
Formation of nitric oxide
Nitric oxide is created by converting L-arginine to nitric oxide, with L-citrulline produced as a by-product. L-arginine is converted to NO by the enzyme nitric oxide synthase (NOS) which exists in three isoforms. 2, 3 A neuronal form (nNOS) is involved in neurotransmission. 2 An inducible form (iNOS) is generated by inflammatory mediators and is thought to be responsible for the low blood pressure associated with septic shock. 2 The third isoform, endothelial nitric oxide synthase (eNOS), is involved in the regulation of vascular tone. 2 eNOS produces NO, which acts on endothelial smooth muscle cells to cause a rise in smooth muscle cyclic-GMP (see Figure 1 ), leading to smooth muscle relaxation and vasodilation. 2, 3 Several co-factors are required for NO biosynthesis. These include reduced nicotinamide adenine dinucleotide phosphate (NADPH), flavin mononucleotide, flavin adenine dinucleotide (FAD), tetrahydrobiopterin (BH 4 ), and calmodulin. 2, 3 
Therapeutic applications of nitric oxide in the intensive care unit
Inhaled NO was first studied in lambs in 1991, where it was found to vasodilate the pulmonary vasculature. 4, 5 The potential therapeutic applications of a vasodilatory molecule that could be delivered directly to the blood vessels of the lung has been of great interest to medical practitioners dealing with a range of conditions that involve pulmonary hypoxic vasoconstriction ever since.
Inhaled nitric oxide (iNO) has been used to treat persistent pulmonary hypertension in the newborn, in congenital heart disease, and in acute right heart failure. 5 There have also been reports of its use in acute sickle cell disease chest crisis 6 and early animal research suggests that it may be of benefit in cerebral malaria. 7 This review will focus on the use of iNO in acute respiratory distress syndrome (ARDS) patients in the intensive care setting.
ARDS was first described in 1967 in a case series reporting 12 patients who had developed respiratory failure associated with diffuse bilateral pulmonary infiltrates, decreased lung Nitric oxide is a potent vasodilator which when inhaled causes dilatation in the pulmonary vasculature. It is this action that has been studied in intensive care medicine, especially in relation to hypoxic vasoconstriction associated with acute respiratory distress syndrome (ARDS). The use of inhaled nitric oxide has been shown to improve ventilation:perfusion matching, and thus to improve oxygenation. This article reviews the chemistry and clinical properties of nitric oxide as well as its potential uses, clinical effectiveness and side effects. The authors also surveyed UK intensive care units to review the current prevalence of the use of inhaled nitric oxide. It was found that while the majority do not currently use inhaled nitric oxide in ARDS patients, it had still been used in 27% (n=61) of the departments surveyed. compliance and hypoxaemia that did not improve with supplemental oxygenation. 9 Following this, it was recognised that a wide range of critically ill patients suffering from different pathologies were experiencing a similar collection of symptoms, which has since become known as ARDS. While the risk factors for developing ARDS have been identified, it is still not clear why some people progress to ARDS and other people, despite very similar precipitating conditions, do not. 9 Some of the conditions associated with ARDS include the sepsis syndrome, pneumonia, lung contusion, aspiration of gastric contents, pancreatitis, trauma and multiple transfusions. 9, 10 ARDS is characterised by three overlapping phases. [8] [9] [10] Firstly, there is an inflammatory or exudative phase, in which there is widespread cytokine release, endothelial damage and non-cardiogenic pulmonary oedema. Secondly, there is a proliferative phase in which the oedema begins to resolve and myofibroblasts begin to predominate in the affected lung, with the result that fibrin is deposited into the lung intra-alveolar space and into the alveoli themselves. 8 The final fibrotic stage occurs in a proportion of patients with ARDS and involves the fibrin being replaced by collagen leading to fibrosis. The changes to lung architecture occur preferentially in the dependant lung 11 and lead to a stiff lung that is difficult to ventilate. The end result is a ventilation/perfusion mismatch leading to respiratory failure. 11 ARDS has a mortality rate of up to 40-50% 12, 13 and the long-term sequelae of ARDS include a restrictive lung defect and impaired pulmonary gas exchange. 14 Inhaled NO is a logical treatment choice for ARDS patients, as inhaling the molecule allows it to act on the pulmonary vasculature immediately adjacent to the ventilated lung. This increase in local blood flow around the alveolar units therefore matches perfusion to ventilation. 15, 16 The effect is to improve oxygenation and decrease the strain on the right heart caused by hypoxic vasoconstriction. 6, 15, 16 Inhaled NO therapy is associated with a decrease in pulmonary artery pressure and a lower incidence in the rate of severe respiratory failure. 17 There is also an improved oxygenation index in patients managed with iNO, which is statistically significant. In the long term, iNO therapy has been shown to be associated with improved lung function tests six months post-discharge. 14 Patients were found to have better than predicted total lung capacity (TLC), forced expiratory volume in one second (FEV 1 ), forced vital capacity (FVC), and FEV 1 /FVC ratio. 14
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Other considerations in nitric oxide therapy
There are a number of factors that need to be taken into account considering the use of NO as a treatment option. The financial implications of introducing a new treatment modality are a concern. A course of iNO treatment averaging 30.2 hours has been found to cost up to US $15,000, with a mean cost of US $6,417 in a study examining iNO use in patients following cardiac surgery. 18 Inhaled NO also has a significant dose variability required to achieve a therapeutic effect. It has been found that the maximal improvement in oxygenation can occur at concentrations as low as 1-2 parts per million (ppm), or up to 10 parts per million. 19, 20 Doses above 10 ppm were found to be of minimal benefit, as oxygenation did not improve and the response to iNO disappeared in some patients treated with higher doses. 19 The most important finding in relation to iNO in ARDS is that while the literature demonstrates an improvement in physiological parameters, there has not been an improvement in mortality. 17, 21 A 2011 Cochrane Collaboration review of iNO reported 14 randomised controlled trials with 1,303 participants and found that iNO did improve oxygenation but did not improve survival. 17 Of note, the improvement in oxygenation was found to be only statistically significant for the first 24 hours after initiation of treatment. 17, 21 Secondary endpoints of ventilator-free days and length of stay in ICU showed statistically insignificant effects. 17 In view of the lack of a survival benefit, the next question is whether iNO has any risks associated with its use. There were early concerns that iNO therapy could cause systemic vasodilation. 22 This property was initially discounted and it was thought that NO reacted with haemoglobin to be converted to nitrate and methaemoglobin by nitric oxide dioxygenase, limiting the half-life of NO to less than a second. 23 However, subsequent research has shown that in an oxygenated environment, iNO binds to the beta subunit of the haemoglobin molecule. 24 NO will then dissociate from the beta subunit in the deoxygenated state, causing peripheral vasodilation in areas of low oxygenation. 24 This peripheral vasodilation may be an issue in some patients on the intensive care unit. A review article by Coggins et al gives a more thorough review of the mechanisms for this action. 24 Inhaled NO' s other potentially harmful side effects include production of methaemoglobin, which can produce a relative anaemia and thus methaemoglobin levels must be monitored in patients using iNO. 25 Nitric oxide can also combine with water to form nitrogen dioxide, nitrous acid and nitric acid, which can damage lung tissues. 14, 26 There has, however, been recent research that suggests haemoglobin acts to convert nitrite back into NO. 27, 28 The normal physiological action of NO can produce negative results in severely unwell patients. NO is involved in the regulation of vascular tone in the renal blood vessels and it has been found that iNO use is associated with an increase in the rate of renal impairment in critically ill patients. 17 This is all the more relevant when it is considered that acute kidney injury is in itself a negative indicator for survival to discharge of patients admitted to intensive care. 29
Review of inhaled NO use in the UK
The authors have investigated whether clinicians are using iNO in the UK.
The aim was to gain an awareness of whether, regardless of the literature, clinicians were using iNO. While evidence-based medicine is important, there is also a need for critical appraisal by individual clinicians about whether to institute therapies rather than blindly following guidelines. 30 Appropriate critical appraisal allows doctors to establish whether the research they are reading is robust enough to enforce a change in their practice. There have been issues about the research into iNO. The Cochrane review was only able to grade the research into this topic as being of low-tomoderate quality, due to the presence of various sources of bias, and a UK-based meta-analysis found that most trials used a fixed dosing regimen which may have been inappropriate as patients can become sensitised to iNO. 19 Additionally, Gerlach et al reviewed the dose-response curves of patients given iNO. They found that continuous treatment with iNO, as used in a large number of trials into this drug, 21 caused a left-shift of the dose-response curve for oxygenation and pulmonary vascular resistance. 19 Some patients are sensitive to lower doses of iNO and some patients became non-responders to higher doses. 19 This can accentuate toxic side effects, while reducing the benefits of iNO therapy. 19, 21 Adhikari et al also considered the possibility that even though research does not support a mortality benefit, there may still be a role for its use in specific sub-groups of patients, such as patients with life-threatening refractory hypoxaemia, where the use of iNO may buy some time to allow other standard therapies to work. 21 The question is whether clinicians feel that iNO does offer a clinical benefit despite the research not backing up a benefit in mortality. 17, 21 We carried out a questionnaire study, surveying 225 intensive care units in the UK. The hospitals included were from a range of areas throughout the UK and included large specialist tertiary centres, teaching hospitals, and district general hospitals. We spoke to the charge nurse for each department and asked a range of questions about their service. One of the questions was whether, to the best of their knowledge, their department had used iNO in the last 12 months. The majority denied using iNO, with 73% (n=164) of the units surveyed reporting that they had not used iNO, and 27% (n=61) of the departments reporting they had used iNO.
These results indicate that in the majority of cases UK clinicians are following international guidelines in regards to the use of iNO.
Discussion
The goal of improving mortality in ARDS patients by treating hypoxaemia and improving tissue oxygenation using iNO, while common sense, has not been shown to be effective. There have been a number of theories put forward to explain why improving oxygenation has not improved mortality in this patient group. 17, 21 An important consideration is that ARDS is the endpoint of a wide range of different pathologies. ARDS patients are by definition, severely unwell and are often suffering multiple organ dysfunction. 8, 9, 21 The cause of death is not necessarily related to refractory hypoxaemia, but can be related to the underlying pathology or multi-organ failure related to sepsis, [31] [32] [33] for which iNO therapy has no role. Finding one treatment that can improve outcomes in this diverse group of patients has proven to be an elusive goal. Further research is required to discover new therapies that will improve the high mortality rate associated with ARDS. However, as the available literature in this field has consistently been unable to demonstrate a mortality benefit for the use of iNO, it is difficult to find justification for the routine use of iNO in ARDS patients. It is also important to recognise the hazards associated with iNO treatment and realise that there is a definite risk that the treatment may do more harm than good.
